Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 7/20 | 0.40 |
| ▸ | TP53 | P04637 | 2/20 | 0.40 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | RAD52 | P43351 | 1/20 | 0.38 |
| ▸ | MITF | O75030 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5224391 | 0.80 | KMT2A (0.55) | ALDH1A1MAPTTP53CXCR3MEN1 | |
| Bromide SCHEMBL8915312 | 0.78 | KMT2A (0.54) | ALDH1A1MAPTTP53CXCR3MEN1 | |
| Hydrochloric Acid SCHEMBL6030424 | 0.78 | KMT2A (0.54) | ALDH1A1MAPTTP53CXCR3MEN1 | |
| Bromide SCHEMBL9774783 | 0.77 | KMT2A (0.52) | ALDH1A1MAPTTP53CXCR3MEN1 | |
| SCHEMBL900835 | 0.76 | ALDH1A1 (0.45) | ALDH1A1MAPTTP53MEN1KMT2A | |
| SCHEMBL7963421 | 0.75 | MEN1 (0.60) | ALDH1A1MAPTTP53MEN1KMT2A | |
| SCHEMBL14349578 | 0.74 | MAPT (0.47) | ALDH1A1MAPTTP53CXCR3MEN1 | |
| Bromide SCHEMBL11839601 | 0.74 | ALDH1A1 (0.56) | ALDH1A1MAPTTP53RAB9ALMNA | |
| SCHEMBL8274718 | 0.72 | KMT2A (0.49) | ALDH1A1MAPTTP53CXCR3MEN1 | |
| SCHEMBL31194845 | 0.71 | IRAK4 (0.35) | CXCR3MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070299109-A1 | Dimeric Compounds Of Piperidine, Piperazine Or Morpholine Or Their 7-Membered Analogs Suitable For The Treatment Of Neurodegenerative Disorders | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-12-27 | — | — | US | disclosed |
| US-20070299109-A1 | Dimeric Compounds Of Piperidine, Piperazine Or Morpholine Or Their 7-Membered Analogs Suitable For The Treatment Of Neurodegenerative Disorders | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-12-27 | — | — | US | disclosed |
| WO-2006008259-A1 | DIMERIC COMPOUNDS OF PIPERIDINE, PIPERAZINE OR MORPHOLINE OR THEIR 7-MEMBERED ANALOGS SUITABALE FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070299109-A1 | Dimeric Compounds Of Piperidine, Piperazine Or Morpholine Or Their 7-Membered Analogs Suitable For The Treatment Of Neurodegenerative Disorders | PARK7, SNCA, PSEN2 | ALDH1A1 1172/4885MAPT 7/4885TP53 593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.